Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action

9 Dec 2023

Abstract excerpt

Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors that arise from lipocytes in soft tissue. There is a high unmet need in patients with these liposarcomas given poor outcomes, particularly for DDLPS. WDLPS and DDLPS share important genetic and histological characteristics - most notably, the amplification of the 2 genes MDM2 and CDK4. Both genes are considered oncogenes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38104352
DOI: 10.1016/j.ctrv.2023.102668

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionPMID 38104352Read ↗

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversSemantic proximity Read ↗

Targeting the MDM2-p53 pathway in dedifferentiated liposarcomaSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.Semantic proximity Read ↗

Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells induces dedifferentiated liposarcoma potencySemantic proximity Read ↗

Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphologySemantic proximity Read ↗

Dedifferentiated LiposarcomaSemantic proximity Read ↗

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaSemantic proximity Read ↗

The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcomaSemantic proximity Read ↗

Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunitiesSemantic proximity Read ↗

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy SelectionSemantic proximity Read ↗

Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.